An open-label multicenter phase II study of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors.

Trial Profile

An open-label multicenter phase II study of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Sep 2009 Planned end date (1 Apr 2009) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Actual patient number (11) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top